Drug Trial Radar · NCT05915026
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Aug 16, 2023
Primary completion
Sep 18, 2024
Study completion Sep 25, 2024
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to help children under the age of 18 with any known or suspected problems scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI). MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject a contrast agent into a patient's vein to perform a "contrast-enhanced" MRI (CE-MRI). Such CE-MRI examinations may support doctors to identify certain health problems or improve their evaluation. The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd), which is needed for the increase in signal intensity and contrast in MRI. The gadolinium in these contrast agents is caged in a molecule (chelate complex). Researchers are developing new contrast agents with a lower amount of Gd needed per CE-MRI investigation. Gadoquatrane is one of these new contrast agents. It has been tested in several studies previously. The main purpose of this study is to learn how gadoquatrane moves into, through, and out of the body and how safe it is in children. The researchers will measure the amount of gadoquatrane in the blood at different time points after a single injection. The participants will undergo an MRI examination and receive gadoquatrane once at a dose of 0.04 mmol Gd/kg (corresponding to 0.1 mL/kg). It is injected into the participant's vein (also called an intravenous injection) during the MRI examination. Each participant will be in the study for between 8 and 38 days with up to 5 doctor visits, including the screening phase of up to 28 days with no more than 2 visits. Once a participant has received the injection of gadoquatrane, the remaining study duration is 7 (±1) days. At the start or during the study, the doctors and their study team will: * check the weight and height of the participant, * ask for information including age and medical history, * take participants' blood samples, * ask participants and/or their guardians questions about medicines they are taking, * check blood pressure, heart rate and body temperature, * check the area where the participants had the intravenous injection, * do pregnancy tests in girls of childbearing age, * review the MRI scans obtained in the study and decide on the diagnosis * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Conditions
- Contrast Enhancement in Magnetic Resonance Imaging
- Children
Interventions
Gadoquatrane (BAY1747846)Drug
0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve (AUC) of Gadoquatrane After Single AdministrationTime frame: Up to 8 hours post injection
- Plasma Clearance Normalized to Body Weight (CL/BW) of Gadoquatrane After Single AdministrationTime frame: Up to 8 hours post injection
- Apparent Volume of Distribution at Steady State Normalized to Body Weight (Vss/BW) of Gadoquatrane After Single AdministrationTime frame: Up to 8 hours post injection
- Simulation of Plasma Concentration at 10, 20 and 30 Minutes Post-injection (C10, C20 and C30)Time frame: At 10, 20 and 30 minutes post injection
Locations
34 sites in 10 countries. Site status is shown where the registry gives one.
Halo Diagnostics - Indian Wells
Indian Wells, California
Children's Mercy Hospital Kansas City - Radiology
Kansas City, Missouri
MUSC University Hospital - Radiology
Charleston, South Carolina
Centro de Diagnostico Enrique Rossi | Departamento de Investigacion Clínica
Ciudad Autonoma de Buenos Aire, Ciudad Auton. de Buenos Aires, Argentina
Sanatorio Allende | Departamento de Investigación Clínica
Córdoba, Córdoba Province, Argentina
Clinica Universitaria Reina Fabiola | Consultorios Externos
Córdoba, Córdoba Province, Argentina
University Multiprofile Hospital for Active Treatment St. Ivan Rilski | Radiology Department
Sofia, Bulgaria
University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Radiology Department
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment Sveti Georgi | Base II - Radiology Department
Plovdiv, Plovdiv Province, Bulgaria
Multiprofile Hospital for Active Treatment Central Onco Hospital | Independent Medical Diagnostic Laboratory Mediscan
Plovdiv, Plovdiv Province, Bulgaria
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Children's Hospital Zhejiang University School of Med
Hangzhou, Hangzhou Province, China
West China Second University Hospital
Chengdu, Sichuan, China
Fakultní nemocnice Ostrava
Ostrava - Poruba, Czechia
Fakultni nemocnice Plzen - Lochotin
Pilsen, Czechia
Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Pädiatrische Radiologie
Berlin, Germany
Universitätsklinikum Münster - Klinik für Radiologie, Kinderradiologie
Münster, North Rhine-Westphalia, Germany
Universitätsklinikum Leipzig - Institut für Kinderradiologie
Leipzig, Saxony, Germany
Universitätsklinkum Halle (Saale) - Universitätsklinik und Poliklinik für Radiologie, Kinderradiologie
Halle, Saxony-Anhalt, Germany
Universitätsklinikum Jena - Institut für Diagnostische und Interventionelle Radiologie, Kinderradiologie
Jena, Thuringia, Germany
Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital
Nagoya, Aichi-ken, Japan
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan
Tokai University Hospital
Isehara, Kanagawa, Japan
Kanagawa Children's Medical Center
Yokohama, Kanagawa, Japan
Nara Prefecture General Medical Center
Nara, Nara, Japan
Shizuoka Children's Hospital
Shizuoka, Shizuoka, Japan
Jichi Medical University Hospital
Shimotsuke, Tochigi, Japan
Juntendo University Hospital
Bunkyo, Tokyo, Japan
Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Children's Medical Center
Fuchū, Tokyo, Japan
National Center for Child Health and Development
Setagaya-ku, Tokyo, Japan
Instytut "Pomnik - Centrum Zdrowia Dziecka"
Warsaw, Poland
Karolinska Universitetssjukhuset Solna - Funktion Medicinsk Diagnostik, Barnradiologi
Stockholm, Stockholm County, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.